Download PDF
Thromb Haemost 1985; 54(02): 510-524
DOI: 10.1055/s-0038-1657885
Original Article
Schattauer GmbH Stuttgart

Enhancement of Factor VIII-von Willebrand Factor Ristocetin Cofactor Activity by Monoclonal Antibodies

V Hornsey
The Edinburgh and South-East Scotland Blood Transfusion Service, Royal Infirmary, Edinburgh, UK
,
L R Micklem
*   The Department of Surgery, Edinburgh University, Edinburgh, UK
,
M C McCann
*   The Department of Surgery, Edinburgh University, Edinburgh, UK
,
K James
*   The Department of Surgery, Edinburgh University, Edinburgh, UK
,
J Dawes
**   The MRC/SNBTS Blood Components Assay Group, Edinburgh, UK
,
D B L McClelland
The Edinburgh and South-East Scotland Blood Transfusion Service, Royal Infirmary, Edinburgh, UK
,
C V Prowse
The Edinburgh and South-East Scotland Blood Transfusion Service, Royal Infirmary, Edinburgh, UK
› Author Affiliations
Further Information

Publication History

Received 23 November 1984

Accepted 31 May 1985

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Five monoclonal antibodies to human von Willebrand factor were selected for characterization from 18 produced in murine hybridomas. All showed a high and specific affinity for human von Willebrand factor (vWf) but exhibited little if any crossreaction with sera from other species. The antibodies defined four epitopes on vWf, none of which were involved in platelet binding. Binding of two distinct antibodies at one of these epitopes was associated with enhancement of the rate of vWf-dependent platelet agglutination in the presence of ristocetin. This effect was more noticeable when cryosupernatant plasma was used in place of normal plasma as the source of vWf, and was not explicable simply in terms of antibody-induced cross-linking of vWf.

Keywords

Factor VIII - von Willebrand factor - Ristocetin cofactor - Monoclonal antibody
 

  • References

  • 1 Zimmerman TS, Ruggeri ZM, Fulcher CA. Factor VIII-von Willebrand factor. Prog. Haematol 1983; 13: 279-309
    PubMedGoogle Scholar
  • 2 Sakariassen KS. The role of factor VIII-von Willebrand factor in platelet adherence to human artery subendothelium. Ph D Thesis. 1984. University of Utrecht;
    Google Scholar
  • 3 Over J, Bouma BN, van Mourik JA, Sixma JJ. Heterogeneity of human factor VIII. I. Characterisation of factor VIII present in the supernatant of cryoprecipitate. J Lab Clin Med 1978; 91: 32-46
    PubMedGoogle Scholar
  • 4 Sixma JJ, Sakariassen KS, Beeser-Visser NH, Ottenhof-Rovers M, Bolhuis PA. Adhesion of platelets to human artery sub-endothelium: effect of factor VIII von Willebrand factor of various multimeric compositions. Blood 1984; 63: 128-139
    PubMedGoogle Scholar
  • 5 Andersen JC, Switzer MEP, McKee PA. Support of ristocetin-induced platelet aggregation by procoagulant inactive and plasmincleaved forms of human factor VIII-von Willebrand factor. Blood 1980; 55: 101-108
    PubMedGoogle Scholar
  • 6 Martin SE, Marder VJ, Francis CW, Lofthus LS, Barlow GH. Enzymatic degradation of the factor VIII-von Willebrand protein. A unique tryptic fragment with ristocetin cofactor activity. Blood 1980; 55: 848-858
    PubMedGoogle Scholar
  • 7 Bradley LA, Franco EL, Reisner HM. Use of monoclonal antibodies in an enzyme immunoassay for factor VIII related antigen. Clin Chem 1984; 30: 87-92
    PubMedGoogle Scholar
  • 8 Ogata K, Saito H, Ratnoff OD. The relationship of the properties of antihemophilic factor (factor VIII) that supports ristocetin-induced platelet agglutination (factor VIIIR: RC) and platelet retention by glass beads as demonstrated by a monoclonal antibody. Blood 1983; 61: 27-35
    PubMedGoogle Scholar
  • 9 Goodall AH, Jarvis J, Chand S, Rawlings E, O’Brien DP, McCraw A, Hutton R, Tuddenham EGD. An immunoradiometric assay for human factor VIII-von Willebrand factor using monoclonal antibodies that define a functional epitope. Br J Haematol 1985; 59: 565-577
    CrossrefPubMedGoogle Scholar
  • 10 Fulcher CA, Zimmerman TS. Characterisation of the human factor VIII procoagulant protein with a heterologous precipitating antibody. Proc Natl Acad Sci USA 1982; 79: 1648-1652
    CrossrefPubMedGoogle Scholar
  • 11 Meyer D, Baumgartner HR, Edgington TS. Relative role of intramolecular loci in mediation of platelet adhesion to subendothelium. Br J Haematol 1984; 57: 609-620
    CrossrefPubMedGoogle Scholar
  • 12 Stel HV, Sakariassen KS, Scholte BJ, Veerman ECI, Van der Kwast TH, De Groot PG, Sixma JJ, Van Mourik JA. Characterisation of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to sub-endothelium. Blood 1984; 1408-1415
    PubMedGoogle Scholar
  • 13 Nokes TC, Mahmoud NA, Savidge GF, Goodall AH, Meyer D, Edgington TS, Hardisty RM. Von Willebrand factor has more than one binding site for platelets. Thromb Res 1984; 34: 361-366
    CrossrefPubMedGoogle Scholar
  • 14 Schullek J, Jordan T, Montgomery R. Interaction of von Willebrand factor with human platelets in the plasma milieu. J Clin Invest 1984; 73: 421-428
    CrossrefPubMedGoogle Scholar
  • 15 Bowie EJW, Fass DN, Katzmann JA. Functional studies of von Willebrand factor using monoclonal antibodies. Blood 1983; 62: 146-151
    PubMedGoogle Scholar
  • 16 Katzmann JA, Mujwid DK, Miller RS, Fass DN. Monoclonal antibodies to von Willebrand factor: reactivity with porcine and human antigens. Blood 1981; 58: 530-536
    PubMedGoogle Scholar
  • 17 Kirby EP, Edgington TS. Characterisation of monoclonal antibodies to bovine von Willebrand factor. Thromb Haemostas 1983; 50: 191
    PubMedGoogle Scholar
  • 18 Sola B, Avner P, Sultan Y, Jeanneau C, Maissoneuve P. Monoclonal antibodies against human factor VIII molecule neutralise antihemophilic factor and ristocetin cofactor activities. Proc Natl Acad Sci USA 1982; 79: 183-187
    CrossrefPubMedGoogle Scholar
  • 19 Booth WJ, Furby FH, Bennet MC, Castaldi PA. Factor VIII-von Willebrand factor has potent lectin activity. Biochem Biophys Res Comm 1984; 118: 495-501
    CrossrefPubMedGoogle Scholar
  • 20 Meyer D, Zimmermann TS, Obert B, Edgington TS. Hybridoma antibodies to human von Willebrand factor. I. Characterisation of seven clones. Br J Haematol 1984; 57: 597-608
    CrossrefPubMedGoogle Scholar
  • 21 Laurell CB. Electroimmunoassay. Scand J Clin Lab Invest 1972; 29 (Suppl. 124) 21-37
    CrossrefPubMedGoogle Scholar
  • 22 Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson JA. A method for assaying von Willebrand factor (ristocetin cofactor). Thrombos Diathes Haemorrh 1975; 34: 306-308
    PubMedGoogle Scholar
  • 23 Prowse CV, Sas G, Gader AMA, Cort JH, Cash JD. Specificity in the factor VIII response to vasopressin. Br J Haematol 1979; 41: 437-447
    CrossrefPubMedGoogle Scholar
  • 24 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 25 Salacinski PRR, McLean C, Sykes JEC, Clement-Jones CV, Lowry PJ. Iodination of proteins, glycoproteins and peptides using a solid phase oxidising agent (Iodogen). Anal Biochem 1981; 117: 996-1003
    PubMedGoogle Scholar
  • 26 Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, Franatoni J, Green D, Hampton J, Hilgartner M, Levine P, Lazerson J, McMillan C, Penner J, Shapiro S, Schulman NR. A more uniform measurement of factor VIII inhibitors. Thrombos Diathes Haemorrh 1975; 34: 869-872
    PubMedGoogle Scholar
  • 27 Dawes J, James K, Micklem LR, Pepper DS, Prowse CV. Monoclonal antibodies directed against human thrombin and the thrombin-anti-thrombin complex. Thromb Res 1984; 36: 397-409
    CrossrefPubMedGoogle Scholar
  • 28 Kohn J, Wilchek M. A new approach (cyano-transfer) for cyanogen bromide activation of Sepharose at neutral pH, which yields activated resins free of interfering nitrogen derivatives. Biochem Biophys Res Comm 1982; 107: 878-884
    CrossrefPubMedGoogle Scholar
  • 29 Wright JF, Hunter WM. A convenient replacement for cyanogen bromide-activated solid phases in immunoradiometric assays. J Immunol Methods 1982; 48: 311-325
    CrossrefPubMedGoogle Scholar
  • 30 Hunter WM. Simplified solid phase radioimmunoassay without centrifugation. Acta Endocrinol 1977; 85 (Suppl. 212) 463
    PubMedGoogle Scholar
  • 31 Griffin BD, Micklem LR, James K, McCann MC, Pepper DS. Production of monoclonal antibodies to human factor VIII coagulant protein. Hybridoma 1984; 3: 102
    PubMedGoogle Scholar
  • 32 Hunter NR, Dawes J, MacGregor IR, Pepper DS. Quantitation by radioimmunoassay of thrombospondin synthesised and secreted by human endothelial cells. Thromb Haemostas 1985; 52: 288-291
    PubMedGoogle Scholar
  • 33 Heiler G, Fass DN, Katzmann JA. Spontaneous platelet aggregating activity produced by von Willebrand factor modified by monoclonal antibodies. Circulation 1982; 66: 298
    PubMedGoogle Scholar
  • 34 Melero JA, Gonzalez-Rodriquez J. Preparation of monoclonal antibodies against glycoprotein IIIa of human platelets: their effect on platelet aggregation. Eur J Biochem 1984; 141: 421-427
    CrossrefPubMedGoogle Scholar
  • 35 Coller BS. Biochemical and electrostatic considerations in primary platelet aggregation. Ann NY Acad Sci 1983; 416: 693-708
    CrossrefPubMedGoogle Scholar
  • 36 Senogles SE, Nelsestuen GL. Von Willebrand factor: a protein which binds at the cell surface interface between platelets. J Biol Chem 1983; 258: 12327-12333
    PubMedGoogle Scholar
  • 37 Furlan M, Perret B, Beck EA. Von Willebrand activity of low molecular weight human factor VIII increases by binding to gold granules. Thromb Haemostas 1981; 45: 242-246
    PubMedGoogle Scholar